Protagonist Therapeutics Inc (PTGX)
Return on equity (ROE)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 275,188 | -78,955 | -123,413 | -122,627 | -66,150 |
| Total stockholders’ equity | US$ in thousands | 675,295 | 336,677 | -536,755 | -409,362 | -283,811 |
| ROE | 40.75% | -23.45% | — | — | — |
December 31, 2024 calculation
ROE = Net income ÷ Total stockholders’ equity
= $275,188K ÷ $675,295K
= 40.75%
The return on equity (ROE) for Protagonist Therapeutics Inc has varied significantly over the years, based on the provided data. In December 31, 2023, the company's ROE was -23.45%, indicating that the company incurred a loss relative to its equity during that period. However, by December 31, 2024, the ROE improved substantially to 40.75%, showing a significant rebound and profitability for the company. This positive swing suggests that the company effectively utilized its equity to generate profits and create value for its shareholders. Monitoring ROE trends can provide insights into the company's financial performance and management efficiency.
Peer comparison
Dec 31, 2024